PF-Atlas › Treatments › TERT Gene Therapy

TERT Gene Therapy

AAV-TERT restores telomere length in AEC2s — addresses genetic root cause

Clinical research — In human clinical trials (Phase I–III). How PF-Atlas grades evidence.
Development stage
Preclinical→Phase I
Evidence level
Level 3 (Preclinical)
Mechanism class
AAV-TERT restores telomere length in AEC2s — addresses genetic root cause
Timeline
3-6 years
Risk profile
Medium
Developer
Telomere Therapeutics
Key researchers
E. Cogan

Overview

TERT/TERC mutations in ~8-15% sporadic IPF and 25% familial IPF. Strongest genetic association of any common lung disease.

How TERT Gene Therapy fits into IPF treatment

TERT Gene Therapy is classified as Level 3 (Preclinical) at the Preclinical→Phase I stage. Explore how it compares to other options and where it sits in the development pipeline:

TERT Gene Therapy drug profileAAV-TERT restores telomere length in AEC2s — addresses genetic root causeClinical trialsDrug pipelineResearch

Other IPF treatments

Nerandomilast / JascaydInhaled Treprostinil / TyvasoAdmilparant / BMS-986278Rentosertib / ISM001-055AI Knowledge GraphuPAR-CAR-T Senolytic Immunotherapy
Medical disclaimer. This page summarizes published research and PF-Atlas model output about TERT Gene Therapy for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.